000			02866nam a22004697a 4500
008			181214s20182018 xxu||||| |||| 00| 0 eng d
022			_a0960-7404
024			_a10.1016/j.suronc.2018.08.005 [doi]
024			_aS0960-7404(18)30055-0 [pii]
040			_aOvid MEDLINE(R)
099			_a30449489
245			_aSclerosing encapsulating peritonitis as a potential complication of cytoreductive surgery and HIPEC: Clinical features and results of treatment in 4 patients.
251			_aSurgical Oncology. 27(4):657-662, 2018 Dec.
252			_aSurg Oncol. 27(4):657-662, 2018 Dec.
253			_aSurgical oncology
260			_c2018
260			_fFY2019
265			_sppublish
266			_d2018-12-14
520			_aCopyright (c) 2018 Elsevier Ltd. All rights reserved.
520			_aSclerosing encapsulating peritonitis (SEP) is a rare entity characterized by encapsulation of the small bowel and/or the colon by a fibrous tissue that forms a shell. Intraperitoneal chemotherapy (IPC) has been reported to be a potential causative factor of secondary SEP. However, few studies have reported on secondary SEP related to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Here, we review results from four clinical cases of SEP associated with CRS and HIPEC. In all four patients, additional surgery was necessary to alleviate recurrent episodes of small bowel obstruction. These obstructions can occur as early as several weeks after CRS plus HIPEC or as late as 3 years after treatment. Of utmost importance is the prevention of fistulization which can result in enteric contamination of the peritoneal space. To date, no solution to SEP has been identified except additional surgery but it is evident that these reoperative experiences are difficult for both surgeon and patient. The etiopathogenesis of SEP in this setting remains unknown but it is clear that it is related to chronic inflammation of the peritoneum. Large studies are needed to identify the incidence and potential common causes of SEP after CRS and HIPEC.
546			_aEnglish
650			_a*Cytoreduction Surgical Procedures/ae [Adverse Effects]
650			_a*Peritoneal Neoplasms/co [Complications]
650			_a*Peritoneal Neoplasms/su [Surgery]
650			_a*Peritonitis/et [Etiology]
650			_a*Peritonitis/pa [Pathology]
650			_aAdult
650			_aAged
650			_aFemale
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aPeritoneal Neoplasms/sc [Secondary]
650			_aPrognosis
651			_aWashington Cancer Institute
657			_aJournal Article
700			_aSugarbaker, Paul H
790			_aLiberale G, Sugarbaker PH
856			_uhttps://dx.doi.org/10.1016/j.suronc.2018.08.005 _zhttps://dx.doi.org/10.1016/j.suronc.2018.08.005
942			_cART _dArticle
999			_c3950 _d3950